SLC38A4: A Potential Drug Target and Biomarker for Amino Acid Transporter 3

Target Name: SLC38A4

NCBI ID: G55089

SLC38A4

SLC38A4: A Potential Drug Target and Biomarker for Amino Acid Transporter 3

Abstract:

SLC38A4, a member of the SLC family, is a protein that has been identified as a drug target and a potential biomarker for amino acid transporter 3 (AAT3) function. This study aims to provide an in-depth analysis of SLC38A4, its function, and its potential as a drug target and biomarker.

Introduction:

Amino acid transporter 3 (AAT3) is a protein that plays a crucial role in the regulation of amino acids in the body. It is expressed in various tissues and cells and is involved in the transmembrane transport of amino acids across the endoplasmic membrane. AAT3 dysfunction has been implicated in various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and mood disorders. Therefore, there is a growing interest in developing drugs that can modulate AAT3 function to treat these disorders.

SLC38A4: A Potential Drug Target

SLC38A4 is a member of the SLC family, which includes several proteins that play a crucial role in the regulation of various intracellular processes, including protein transport and metabolism. SLC38A4 is expressed in various tissues and cells and is involved in the regulation of amino acids, including glutamine, which is an essential amino acid that plays a crucial role in the regulation of cell growth, metabolism, and stress resistance.

SLC38A4 has been shown to interact with several protein substrates, including AAT3. These interactions suggest that SLC38A4 may be a drug target that can modulate AAT3 function. Therefore, SLC38A4 is a potential drug target that can be targeted with small molecules or other therapeutic agents.

SLC38A4 as a Biomarker

SLC38A4 can also be used as a biomarker for AAT3 function. The expression and function of SLC38A4 have been shown to be regulated by various factors, including genetic and environmental factors. Therefore, the expression level of SLC38A4 can be used as a biomarker for the function of AAT3.

SLC38A4 has been shown to play a role in the regulation of amino acid homeostasis, which is critical for the proper functioning of the body. It has been shown to regulate the transport of amino acids across the endoplasmic membrane and to play a role in the regulation of protein synthesis and metabolism.

Conclusion:

SLC38A4 is a protein that has been shown to interact with AAT3 and to play a role in the regulation of amino acid homeostasis. Its expression and function have been shown to be regulated by various factors, including genetic and environmental factors. Therefore, SLC38A4 is a potential drug target and biomarker for AAT3 function. Further studies are needed to determine its full role in the regulation of AAT3 function and its potential as a therapeutic agent.

Protein Name: Solute Carrier Family 38 Member 4

Functions: Symporter that cotransports neutral amino acids and sodium ions from the extraccellular to the intracellular side of the cell membrane (PubMed:11342143, PubMed:19015196, PubMed:33928121). The transport is electrogenic, pH dependent and partially tolerates substitution of Na(+) by Li(+) (PubMed:11414754). Preferentially transports smaller amino acids, such as glycine, L-alanine, L-serine, L-asparagine and L-threonine, followed by L-cysteine, L-histidine, L-proline and L-glutamine and L-methionine (PubMed:11414754, PubMed:33928121)

The "SLC38A4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC38A4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets